<DOC>
	<DOC>NCT00464971</DOC>
	<brief_summary>This trial was conducted in the United States of America (USA). This trial aimed to evaluate safety and efficacy of 17-beta Estradiol in the treatment of atrophic vaginitis.</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Generally healthy Postmenopausal Hysterectomized or nonhysterectomized Moderate or severe vaginal dryness and soreness Successful completion of the study VAG/PD/009/USA Known, suspected, or past history of breast cancer Known, suspected, or past history of hormonedependent tumor Genital bleeding of unknown etiology Acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use Subjects who had adverse events during the final visit, or discontinued prematurely, or were noncompliant in VAG/PD/009/USA Exposure to any investigational new drug (other than what was dispensed in VAG/PD/009/USA) within the previous 30 days</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>